Comparing Alliqua Biomedical (ALQA) & VWR (VWR)

Alliqua Biomedical (NASDAQ: ALQA) and VWR (NASDAQ:VWR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, risk, profitability, analyst recommendations and dividends.


This table compares Alliqua Biomedical and VWR’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alliqua Biomedical -155.55% -110.42% -65.28%
VWR 4.11% 11.79% 3.67%

Earnings & Valuation

This table compares Alliqua Biomedical and VWR’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alliqua Biomedical $18.24 million 0.45 -$28.24 million ($9.86) -0.17
VWR $4.51 billion 0.97 $148.20 million $1.14 29.17

VWR has higher revenue and earnings than Alliqua Biomedical. Alliqua Biomedical is trading at a lower price-to-earnings ratio than VWR, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

96.7% of VWR shares are held by institutional investors. 15.8% of Alliqua Biomedical shares are held by insiders. Comparatively, 35.5% of VWR shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Alliqua Biomedical and VWR, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alliqua Biomedical 0 1 2 0 2.67
VWR 0 1 1 0 2.50

Alliqua Biomedical currently has a consensus price target of $10.10, indicating a potential upside of 512.12%. VWR has a consensus price target of $32.00, indicating a potential downside of 3.76%. Given Alliqua Biomedical’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Alliqua Biomedical is more favorable than VWR.


VWR beats Alliqua Biomedical on 9 of the 12 factors compared between the two stocks.

About Alliqua Biomedical

Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers SilverSeal.

About VWR

VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC. The Americas segment consists of operations located principally in the United States and Canada, as well as in Puerto Rico, Mexico and select countries in Central and South America, including Costa Rica, Brazil, Argentina and Chile. As of December 31, 2016, the Americas segment included 67 facilities located in eight countries. As of December 31, 2016, the EMEA-APAC segment consisted of its operations located principally in Europe, as well as in certain Asia-Pacific countries, and included 110 facilities located in 26 countries. The Company’s portfolio includes chemicals, reagents, consumables, durable products and scientific equipment and instruments.

Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with's FREE daily email newsletter.

Leave a Reply